Aquestive Therapeutics Net Profit Margin Growth & History (AQST)
Aquestive Therapeutics's net profit margin was −188.09% for fiscal 2025.
View full Aquestive Therapeutics company overviewAquestive Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −188.09% | −111.41 pp |
| 2024 | 2024-12-31 | −76.68% | −61.12 pp |
| 2023 | 2023-12-31 | −15.56% | +98.56 pp |
| 2022 | 2022-12-31 | −114.11% | +24.65 pp |
| 2021 | 2021-12-31 | −138.77% | −17.10 pp |
| 2020 | 2020-12-31 | −121.67% | +4.25 pp |
| 2019 | 2019-12-31 | −125.92% | −34.90 pp |
| 2018 | 2018-12-31 | −91.02% | −77.66 pp |
| 2017 | 2017-12-31 | −13.36% | — |
Aquestive Therapeutics quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −165.45% | −30.01 pp |
| Q1 2026 | 2026-03-31 | −55.77% | +207.19 pp |
| Q4 2025 | 2025-12-31 | −244.79% | −101.08 pp |
| Q3 2025 | 2025-09-30 | −120.61% | −35.62 pp |
| Q2 2025 | 2025-06-30 | −135.44% | −121.78 pp |
| Q1 2025 | 2025-03-31 | −262.96% | −156.53 pp |
| Q4 2024 | 2024-12-31 | −143.72% | −82.30 pp |
| Q3 2024 | 2024-09-30 | −84.99% | −69.34 pp |
| Q2 2024 | 2024-06-30 | −13.66% | +30.09 pp |
| Q1 2024 | 2024-03-31 | −106.43% | −178.89 pp |
| Q4 2023 | 2023-12-31 | −61.42% | +54.21 pp |
| Q3 2023 | 2023-09-30 | −15.65% | +93.71 pp |
| Q2 2023 | 2023-06-30 | −43.74% | +79.15 pp |
| Q1 2023 | 2023-03-31 | 72.46% | +180.21 pp |
| Q4 2022 | 2022-12-31 | −115.63% | +145.65 pp |
| Q3 2022 | 2022-09-30 | −109.36% | +0.18 pp |
| Q2 2022 | 2022-06-30 | −122.89% | −42.30 pp |
| Q1 2022 | 2022-03-31 | −107.74% | +24.18 pp |
| Q4 2021 | 2021-12-31 | −261.28% | +23.62 pp |
| Q3 2021 | 2021-09-30 | −109.54% | +90.83 pp |
| Q2 2021 | 2021-06-30 | −80.59% | −69.82 pp |
| Q1 2021 | 2021-03-31 | −131.92% | +56.67 pp |
| Q4 2020 | 2020-12-31 | −284.91% | −207.95 pp |
| Q3 2020 | 2020-09-30 | −200.38% | −52.11 pp |
| Q2 2020 | 2020-06-30 | −10.77% | +173.18 pp |
| Q1 2020 | 2020-03-31 | −188.59% | −72.12 pp |
| Q4 2019 | 2019-12-31 | −76.96% | +5.92 pp |
| Q3 2019 | 2019-09-30 | −148.27% | −34.92 pp |
| Q2 2019 | 2019-06-30 | −183.95% | +78.06 pp |
| Q1 2019 | 2019-03-31 | −116.48% | −133.98 pp |
| Q4 2018 | 2018-12-31 | −82.88% | −0.55 pp |
| Q3 2018 | 2018-09-30 | −113.35% | −144.48 pp |
| Q2 2018 | 2018-06-30 | −262.01% | −209.09 pp |
| Q1 2018 | 2018-03-31 | 17.51% | +26.37 pp |
| Q4 2017 | 2017-12-31 | −82.34% | — |
| Q3 2017 | 2017-09-30 | 31.13% | — |
| Q2 2017 | 2017-06-30 | −52.93% | — |
| Q1 2017 | 2017-03-31 | −8.86% | — |
Aquestive Therapeutics net profit margin trends
Over the last five fiscal years, Aquestive Therapeutics's net profit margin decreased from −121.67% to −188.09%, a change of −66.42 percentage points. The latest reported quarter, Q2 2026, shows −165.45%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aquestive Therapeutics source filings ↗